The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Topic: Drugs - Primary Care

Wednesday, 24 February 2021
Professor Cliff Bailey and Dr Martin Hadley-Brown discuss the effects of SGLT2 inhibitors on cardiovascular function and their role in the management of CV disease.
Category: Webinars
Wednesday, 10 March 2021
Professor Cliff Bailey and Dr Pam Brown discuss the reno-protective effects of SGLT2 inhibitors and their role in the management diabetic kidney disease.
Category: Webinars
Monday, 17 July 2017
A new study led by the University of Leicester suggests that one in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals. Non-adherence to antihypertensive treatment is a critical contributor to suboptimal blood pressure control.
Tuesday, 04 May 2021
This article highlights the latest guidance on appropriate dosing of direct-acting oral anticoagulants (DOACs) in people with non-valvular atrial fibrillation (NVAF). Key considerations include specific dose adjustment requirements for each DOAC and the importance of improving patient adherence with DOAC therapy.
Category: Editorial
Sunday, 12 March 2017
A new fixed dose combination of saxagliptin (Onglyza) and dapagliflozin (Forxiga) is now available for use in adults with type 2 diabetes.
Category: Have You Heard
Saturday, 09 September 2017
New research has revealed that medication is so effective in reducing the risk of sudden death in patients with heart failure with reduced ejection fraction that the overall benefit of implantable cardioverter-defibrillators (ICDs) is uncertain. The research analysed individual patient data from 12 clinical trials conducted between 1995 and 2014 including 40,000 patients.
Sunday, 12 March 2017
A useful free infographic provides international data on cardiovascular drug adherence. Although the UK lags behind other European countries, it has better adherence rates than the USA, Australia and a number of South American countries.
Category: Have You Heard
Friday, 28 October 2016
Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of a new treatment for heart failure (HF) such as sacubitril/valsartan (Entresto), we must consider not only its acquisition costs but also its potential benefits in improving patients' symptoms and reducing expensive hospital admissions.
Category: Editorial
Monday, 21 November 2016
Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor. This article describes the pharmacist’s role in supporting patients receiving sacubitril/valsartan.
Category: Editorial
Page 2 of 3

Article search and filter